Paradox-breaking RAF inhibitors that also target SRC are effective in drug-resistant BRAF mutant melanoma.
Loading...
Embargo End Date
Authors
Girotti, MR
Lopes, F
Preece, N
Niculescu-Duvaz, D
Zambon, A
Davies, L
Whittaker, S
Saturno, G
Viros, A
Pedersen, M
Suijkerbuijk, BMJM
Menard, D
McLeary, R
Johnson, L
Fish, L
Ejiama, S
Sanchez-Laorden, B
Hohloch, J
Carragher, N
Macleod, K
Ashton, G
Marusiak, AA
Fusi, A
Brognard, J
Frame, M
Lorigan, P
Marais, R
Springer, C
Lopes, F
Preece, N
Niculescu-Duvaz, D
Zambon, A
Davies, L
Whittaker, S
Saturno, G
Viros, A
Pedersen, M
Suijkerbuijk, BMJM
Menard, D
McLeary, R
Johnson, L
Fish, L
Ejiama, S
Sanchez-Laorden, B
Hohloch, J
Carragher, N
Macleod, K
Ashton, G
Marusiak, AA
Fusi, A
Brognard, J
Frame, M
Lorigan, P
Marais, R
Springer, C
Document Type
Journal Article
Date
2015-01-12
Date Accepted
2014-11-07
Abstract
BRAF and MEK inhibitors are effective in BRAF mutant melanoma, but most patients eventually relapse with acquired resistance, and others present intrinsic resistance to these drugs. Resistance is often mediated by pathway reactivation through receptor tyrosine kinase (RTK)/SRC-family kinase (SFK) signaling or mutant NRAS, which drive paradoxical reactivation of the pathway. We describe pan-RAF inhibitors (CCT196969, CCT241161) that also inhibit SFKs. These compounds do not drive paradoxical pathway activation and inhibit MEK/ERK in BRAF and NRAS mutant melanoma. They inhibit melanoma cells and patient-derived xenografts that are resistant to BRAF and BRAF/MEK inhibitors. Thus, paradox-breaking pan-RAF inhibitors that also inhibit SFKs could provide first-line treatment for BRAF and NRAS mutant melanomas and second-line treatment for patients who develop resistance.
Citation
Cancer cell, 2015, 27 (1), pp. 85 - 96
Source Title
Publisher
CELL PRESS
ISSN
1535-6108
eISSN
1878-3686
Collections
Research Team
Gene & Oncogene Targeting
Molecular Drug Resistance
Molecular Drug Resistance